Skip to main content
Go Back to System Level

Clinical trials are studies designed to find new and better ways to treat patients with cancer. Through clinical trials, scientists and physicians at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) are breaking new ground in the development of cancer treatments. Access to clinical trials is an important advantage of receiving your cancer care at UM BWMC.

We offer patients access to some of the 125 clinical trials currently being conducted at UMGCCC in addition to other clinical trials being conducted locally at UM BWMC. In this way, our patients may be eligible for new treatments not yet commercially available elsewhere. If you may be eligible for participation in one of the trials that are currently available, your physician may discuss it with you at the time of your consultation. After discussing the clinical trial with your provider and if you are interested, a research associate will assist in coordinating participation.

Clinical Trials Currently Available at UM BWMC:

Bladder

  • A031803: Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Breast

  • NRG BR007: A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation (DEBRA) for Conservative Treatment of Stage I, Hormone Sensitive, HER2- Negative, Oncotype Recurrence Score less than or equal to 18 Breast Cancer
  • CCTG MA.39: TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer
  • PCG BRE007-12:  Phase II study of Postoperative, Cardiac-Sparing Proton Radiotherapy for Patients with Stage II/III, Loco-Regional, Non-Metastatic Breast Cancer Requiring Whole Breast or Chest Wall Irradiation with Lymph Node Irradiation
  • GCC 18124: Phase II Multi-center Trial Evaluating 5 Fraction S-PBI (Stereotactic Partial Breast Irradiation) for Early Stage Breast Cancer Using the GammaPod
  • GCC 1876: Tumor Bed Dose Delivery using a Breast Specific Radiosurgery Device, The GammaPod: Registry Study and Evaluation of Quality of Life with Development of Sizing Nomogram
  • A191901: Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
  • NRG-CC011: Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial
  • EXActDNA-003: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease (NSABP B-64)

Central Nervous System

  • NRG BN011: Testing the addition of the chemotherapy drug Lomustine (Gleostine) to the usual treatment (Temozolomide and radiation therapy) for newly diagnosed MGMT methylated glioblastoma
  • GCC 20138: Laser interstitial thermal therapy followed by hypofractionated radiation therapy for treatment of newly diagnosed high-grade gliomas
  • GCC 19140: Pilot study of laser interstitial thermal therapy followed by hypofractionated radiation therapy for treatment of recurrent gliomas

Colon

  • NRG-GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) 

Gynecological

  • GCC 1944: A Randomized Phase III Trial of Two Standard Dose Fractionation Regimens for Adjuvant Vaginal Brachytherapy in Early Stage Endometrial Cancer  

Lung

  • SWOG 1827: Testing whether the use of brain scans alone instead of brain scans plus preventive brain radiation affects lifespan in patients with small cell lung cancer
  • GCCC 2449: Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Lung Cancer

Prostate

  • NRG-GU009: Parallel Phase III Randomized Trials for High-Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation
  • NRG-GU010: Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-intensification and Intensification Clinical Trial Evaluation (guidance)
  • GCC 2048: A Phase I Dose Escalation Study of Hypofractionated Accelerated Pelvic Nodal Radiotherapy Delivered with a Simultaneously Integrated Prostate Boost for Patients with Localized, Intermediate- and High-Risk Prostate Cancer
  • GCC 21136: Phase 2 Randomized Total Eradication of Metastatic Lesions Following Definitive Radiation to the Prostate in De Novo Oligometastatic Prostate Cancer (TERPS) Trial

In This Section: